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Abstract
Background: Unintended pregnancy can negatively impact women’s lives and is associated with poorer health
outcomes for women and children. Many women, particularly in low- and middle-income countries, continue to
face obstacles in avoiding unintended pregnancy. In the State of Palestine, a survey conducted in 2006 estimated
that 38% of pregnancies are unintended. In 2014, unmet need for contraception was highest among young
women aged 20–24 years, at 15%.
Mobile phones are increasingly being used to deliver health support. Once developed, interventions delivered by
mobile phone are often cheaper to deliver than face-to-face support. The London School of Hygiene and Tropical
Medicine and the Palestinian Family Planning and Protection Association have partnered to develop and evaluate a
contraceptive behavioural intervention for young women in Palestine delivered by mobile phone. The intervention
was developed guided by behavioural science and consists of short, mobile phone text messages that contain
information about contraception and behaviour change methods delivered over 4 months.
Methods: We will evaluate the intervention by conducting a randomised controlled trial. Five hundred and seventy
women aged 18–24 years, who do not report using an effective method of contraception, will be allocated with a 1:1
ratio to receive the intervention text messages or control text messages about trial participation. The primary outcome
is self-reported acceptability of at least one method of effective contraception at 4 months. Secondary outcomes
include the use of effective contraception, acceptability of individual methods, discontinuation, service uptake,
unintended pregnancy and abortion. Process outcomes include knowledge, perceived norms, personal agency and
intervention dose received. Outcomes at 4 months will be compared between arms using logistic regression.
Discussion: This trial will determine the effect of the intervention on young women’s attitudes towards the most effective
methods of contraception. If the intervention is found to be effective, the intervention will be implemented widely across
Palestine. The results could also be used to design a larger trial to establish its effect on unintended pregnancy.
Trial registration: ClinicalTrials.gov, ID: NCT02905461. Registered on 14 September 2016.
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Background
In 2012, an estimated 85 million pregnancies worldwide
were unintended, half of which ended in abortion [1].
Women who have unintended pregnancies can experi-
ence decreased psychological wellbeing [2–10], initiate
antenatal care later than those with intended pregnan-
cies [4, 10–14] and access care less frequently [4, 11, 14].
There is a higher risk of low birth weight and pre-term
birth among children born of unintended pregnancies
[15, 16] and these children can exhibit behavioural prob-
lems more often than children born of intended preg-
nancies [17]. Unintended pregnancy can also impact the
social wellbeing of parents and families. It can delay or
prevent educational and career achievements, which can
impact the financial security of the family [18]. Unsafe
abortions are a consequence of unintended pregnancy
where access to safe abortion is limited [19, 20]. Satisfying
unmet need for modern contraception reduces unintended
pregnancies and identifying the barriers to non-use is
crucial in achieving this [21, 22].
The conflict in the State of Palestine (the West Bank,
East Jerusalem and the Gaza Strip, hereafter referred to
as ‘Palestine’) has negatively impacted the health and
wellbeing of Palestinians [23–25]. The conflict has also
had negative effects on reproductive health in Palestine
[26, 27]. Data regarding unintended pregnancy in
Palestine generally comes from household surveys where
only married women (sexual activity before marriage is
stigmatised in Palestinian culture) are asked if their
current or last pregnancy was intended at the time that
they became pregnant [28]. Effective contraception
methods are those with a less than 10% typical use-
failure rate at 12 months [29–31]. The (non-permanent)
effective methods available in Palestine are oral contra-
ceptive pills (OCs), intrauterine devices (IUDs), inject-
ables, implants, and the patch. Despite the availability of
these methods, a 2006 survey estimated that 38% of
pregnancies in Palestine are unintended [28, 32].
In 2014, the unmet need for contraception was highest
among young women aged 20–24 years, at 15% [33].
The modern contraceptive prevalence rate among mar-
ried women aged 15–24 years is estimated to be 24%
and the effective rate in the same group is estimated to
be 17% [33]. Barriers to contraceptive uptake are lack of
accurate and comprehensive information about a range of
contraceptive methods, lack of spousal communication
regarding contraception, peers’ and relatives’ (particularly
husband and mother-in-law) disapproval of contraception,
societal pressure to bear children early in marriage and
inadequate family planning services [34–38]. Attitudes,
such as perceived inconvenience and fear of the side
effects of contraceptive methods along with husbands’ op-
position, are common reasons married women provide for
not using contraception [39, 40]. Education also is a factor
in this setting as Palestinian women who spend more time
in education report fewer unintended pregnancies [28]. A
non-representative study in 2014 and found that 55% of
women aged 15–49 years from a community sample (from
underserved areas) said that their pregnancy was unin-
tended (‘unwanted’) and, of these, 26% said that this was
because it ‘was not their choice’. In a client sample (from
service-delivery points), 40% reported unintended preg-
nancy, with 32% saying that it ‘was not their choice’ [41].
Mobile phones are increasingly being used to deliver
health support over a range of health behaviours [42–52].
In sensitive areas, such as reproductive and sexual health,
short messages delivered by mobile phone may be advan-
tageous as they have the potential to be read at a time and
place of the recipient’s choosing. The support can be non-
judgemental and is often more convenient and cheaper to
deliver than face-to-face support. In Palestine, where there
is a substantial area that is underserved with regard to sex-
ual and reproductive health services [41], delivering
contraceptive support by mobile phone may be a particu-
larly advantageous mode by which to reach people. Those
that do have access to services may find the barriers out-
lined above difficult to overcome and may also benefit
from mobile phone support. While there is some evidence
from high-income countries that mobile phone-based in-
terventions can increase contraceptive-related behaviours
[53–55] and knowledge [56], none of the trials evaluating
these interventions had a low risk of bias [57]. To the best
of our knowledge, there is only one trial conducted in a
non-high-income country (Cambodia); this trial found
that post-abortion voice messaging with telephone coun-
selling support increased effective contraceptive use [58].
A systematic approach to developing behaviour change
interventions is recommended [59–61] as it allows for
the intervention to be clearly defined. The London
School of Hygiene and Tropical Medicine (LSHTM) and
the Palestinian Family Planning and Protection Associ-
ation (PFPPA), a Member Association of the Inter-
national Planned Parenthood Federation (IPPF), are
collaborating to evaluate a contraceptive behavioural
intervention delivered by mobile phone for young
women in Palestine. We developed the intervention
guided by an established approach based on behavioural
science [62]. Among other activities, the approach in-
volved consultation with young people, which explored
their knowledge of, attitudes towards, and barriers in,
using contraception; specifying behavioural change;
identifying behaviour change methods and producing
the intervention content through an interactive process
of writing, testing with young people and refining.
In Palestine, mobile phone ownership is high, with
92% of all adults owning a mobile phone and among
people aged 18–34 years, 73% report owning a smart-
phone [63]. However, the intervention development
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process revealed that many young people in Palestine
did not have regular Internet access on their mobile
phones. Those who sometimes access the Internet
though their mobile data said that it is common for the
connection to be lost. Because of this and because many
of the young people we consulted with preferred it, we
identified short messaging service (SMS) as the most
appropriate mode of intervention delivery.
This randomised controlled trial will evaluate the
effect of the intervention on young women’s attitudes
towards the (non-permanent) effective contraceptive
methods available in Palestine: OCs, IUDs, the injection,
the implant, and the patch. Sexual activity before mar-
riage is highly stigmatised in Palestine and there is
strong cultural pressure to bear children soon after mar-
riage. While it is estimated that 24% of women are mar-
ried before age 18 years [33], a significant proportion of
participants in the study population will likely be either
not married (and not sexually active or not willing to
admit that they are) or newly married. Because of this,
an objective primary outcome of effective contraceptive
use would not be advisable as powering a study for an
outcome with a small number of events would make the
sample size prohibitively large. In not-married/not-sexu-
ally-active young women, the intervention aims to in-
crease acceptability of the effective methods for when
they may want to limit or space their families and could
benefit from finding a range of methods acceptable.
This will be the first trial evaluating an intervention
delivered by mobile phone that is designed to increase
the acceptability of effective contraception in Palestine
[57]. The results of the study will contribute to the
growing body of research on the utility of mobile phones
as an intervention-delivery mechanism and contribute to
the evidence base for contraceptive interventions for
young women in Palestine.
Methods
Study design
This study is a parallel-group, individually randomised
superiority trial with a 1:1 allocation ratio evaluating the
effect of a contraceptive intervention delivered by mobile
phone text messaging compared with control text mes-
sages about trial participation. The objective of this re-
search is to establish the effect of the intervention on
young women’s attitudes towards effective contraception
in Palestine.
Eligibility criteria
Women aged 18–24 years, who do not report using
effective contraception, own a personal mobile phone,
live in the West Bank, can provide informed consent
and can read Arabic will be eligible to take part. The
lower age limit of 18 years was chosen because it is the
age in Palestine where people are able to provide inde-
pendent informed consent to take part in research. The
upper age limit of 24 years was chosen because this most
closely matched the target group ‘young people’ [64]
which was identified by the funder. Participants must
also be willing to receive messages about contraception
on their mobile phone.
Recruitment
The trial will be promoted through PFPPA’s service-
delivery points through outreach sites, the PFPPA web-
site, the distribution of trial promotional material via
flyers and social media sites. PFPPA service-delivery
points provide: contraceptive methods; counselling for
women in psychological, legal and social matters; labora-
tory tests for both men and women; maternal, antenatal
and post-natal care and infertility services [65]. The pro-
motional material includes brief information about the
trial (e.g. who is conducting it, who may be eligible, what
participation would involve) with a link to the secure
trial database and randomisation system.
To maximize the chance of recruiting to target,
LSHTM conducted a pre-trial training in Bethlehem to
train local staff on all recruitment procedures. The train-
ing included discussions about the practicalities of re-
cruitment with a view to developing the most
appropriate strategies.
We will report the number of people assessed for eligi-
bility, excluded before randomisation, the number of
participants randomised, allocated to the intervention,
completed follow-up and analysed (Fig. 1. Consolidated
Standards of Reporting Trials (CONSORT) diagram).
Intervention
The intervention is informed by the Integrated Behav-
ioural Model [66] and consists of short mobile phone text
messages providing contraceptive support delivered over
4 months. The intervention messages provide information
about contraception, target beliefs identified in the devel-
opment phase that influence contraceptive use (e.g. mis-
conceptions about the side effects and health risks of
contraception, belief that non-hormonal methods are bet-
ter because they are not harmful to health) and aim to
support young women in believing that they can influence
their reproductive health. The intervention provides ac-
curate information about contraception and contains the
following behaviour change methods, adapted for delivery
by mobile phone [67]: belief selection, facilitation, antici-
pated regret, guided practice, verbal persuasion, tailoring,
cultural similarity, arguments, shifting perspective and
goal setting.
The messages are tailored according to marital status,
resulting in two sets of intervention messages: (1)
female-married and (2) female-not married. Most of the
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messages in the two sets overlap, with minor tailoring so
that the messages are relevant to marital status (a proxy
for sexual activity). Participants allocated to the inter-
vention group receive zero to three messages per day
(113 messages for female-not married and 120 messages
for female-married) for 120 days.
The message sets start with 6 days of messages (10 mes-
sages for married women and 11 for not-married women)
with general information about the study, such as infor-
mation about what they will receive over the next 120 days,
how to stop the messages, who to contact if they change
their number, how to keep the messages private and infor-
mation about who to call if they feel unsafe as a result of
someone reading the messages. Included in the interven-
tion messages that the intervention recipients receive are
seven control messages about the importance of their par-
ticipation and reminding them to contact the project
coordinator if they change their number. On days 119 and
120, the message sets include four messages that indicate
that the messages have ended, provide information on
how to complete the follow-up questionnaire, reassurance
that the information that they provide is confidential and
a final message stating that their participation is helping
to determine the best ways to provide reproductive health
services in Palestine.
Details regarding the development of the intervention
and intervention description will be reported in a forth-
coming publication.
Control
Participants allocated to the control group receive 16
messages over 120 days. The first 4 days include six
messages that introduce the study, provide information
about what they will receive over the next 120 days, how
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) diagram
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to stop the messages and who to contact if they change
their number (e.g. ‘Thank you for joining. This study is
being conducted by Palestinian Family Planning and
Protection Association’; ‘Over the next 4 months, we will
send you a few messages a month’). They will then
receive two messages a month for 3 months – one about
the importance of their participation and one reminding
them to contact the project coordinator if they change
their number (e.g. ‘Your participation in the study is a
way to actively be involved in matters that affect your
life. Thanks’; ‘If you change your number, please contact
X to let us know’). On day 105, participants will receive
one message about the importance of their participation
(‘Your participation helps in reducing inequalities in
reproductive health for youth’). On day 120, they will
receive three messages that provide information on how
to complete the follow-up questionnaire, reassurance
that the information that they provide is confidential
and a final message stating that their participation is
helping to determine the best ways to provide repro-
ductive health services in Palestine (e.g. ‘It is time to
complete the final questionnaire. Research staff will call
you in few days or you can complete it here LINK’; ‘You
are helping us determine the best ways to provide repro-
ductive health services in Palestine’).
All participants will receive usual care and will be free
to seek any other support, whether existing or new.
Outcomes
Primary outcome
The primary outcome is the proportion of participants
reporting that at least one method of effective contra-
ception is acceptable at four months post randomisation.
The acceptability of each method is binary (acceptable/
not acceptable), but is derived from ordinal data from
the following stems: Using the [method]… causes infer-
tility, …causes unwanted side effects, …is easy, …is a
good way to prevent pregnancy and I would recommend
the [method] to a friend. The IUD and implant include
an additional stem: The [method] insertion would not be
a problem for me. The response options for each scale
are: strongly disagree, disagree, not sure, agree, strongly
agree and I do not know what the [method] is. A
method is acceptable if participants report ‘agree’ or
‘strongly agree’ for all scales except for ‘…causes infertil-
ity’ and ‘…causes unwanted side effects’ stems, for which
‘disagree’ or ‘strongly disagree’ denotes acceptability
(items 1-27 in Additional file 1 and items 4-30 in
Additional file 2).
Secondary outcomes
Secondary outcomes are: the proportion reporting
current use of effective contraception (use of effective
contraception); the proportion reporting that each
effective contraceptive method is acceptable (acceptabil-
ity of individual methods); the proportion reporting use
of effective contraception at any time during the four
months (discontinuation); the proportion reporting
attending a sexual health service during the four months
(service uptake); the proportion reporting that they
became pregnant and did not want to become pregnant
during the study (unintended pregnancy); the proportion
reporting having an abortion during the study (induced
abortion).
Process outcomes The process outcomes are: know-
ledge of effective contraception; perceived norms and
personal agency in relation to using and communicating
with partners about contraception; intention to use
effective contraception and intervention dose received.
Data collection
Data will be collected at baseline and at 4 months post
randomisation using questionnaires, which we tested for
face validity with the target group. We asked people to
comment on the length of the questionnaires, the com-
prehensibility of the questions, the meaning of the scales
and suggestions for improvement. All data will be
entered onto the trial database and randomisation sys-
tem, which is on LSHTM’s secure server. At both time
points, participants can either fill out a paper-based ver-
sion of the questionnaire at the recruitment site, provide
the data over the phone with research staff or enter data
directly onto the online system, according to their pref-
erence. If participants provide their questionnaire data
by paper or over the phone, research staff will enter this
data onto the system.
Baseline data collected
At baseline we will measure the primary outcome and
collect the following personal and demographic data: full
name; mobile phone number; email address; date of
birth; marital status; number of children; residence; oc-
cupation; education level; current pregnancy intention;
current method; how they heard about and enrolled in
the study and the time that they prefer to receive the
messages (see Additional file 1).
Follow-up data collected
At 4 months, we will measure the primary, secondary
and process outcomes and collect the following data: if
participants report using an effective method, where
they obtained it; current pregnancy intention; whether
they knew someone else that took part in the study and,
if so, if they read each other’s messages (contamination);
if they have experienced physical violence since being in
the study and if anything good or bad happened as a re-
sult of receiving the messages (see Additional file 2).
McCarthy et al. Trials  (2017) 18:454 Page 5 of 11
Staff unaware of partcipants’ allocation will contact par-
ticipants by phone to collect the follow-up data (partici-
pants can also complete the questionnaire online or
attend the service). For participants who report use of
effective contraception at follow-up, local research staff
will attempt to locate the service records to objectively
verify use.
Methods to improve the quality of data collection
Closer to the start of follow-up, we will conduct a ‘fol-
low-up refresher’ with staff who will collect follow-up
data over the phone. This training will re-emphasise
how to collect the follow-up data in a neutral, standar-
dised way. Staff will also be given a suggested script and
guidelines to follow when gathering the data.
Methods to maximize follow-up response
The pre-trial training also included training in follow-
up procedures. It emphasised the importance of en-
suring that participants understand that participation
involves completing a 4-month questionnaire and to
potentially receiving daily messages about contracep-
tion for 4 months. The control messages, also sent to
participants allocated to the intervention, are an effort
to keep participants engaged. Staff will contact non-
responders up to three times for their follow-up data.
Follow-up will end 6 months after the last participant
has been randomised or after staff have attempted to
contact all non-responders three times, whichever
comes first.
See Fig. 2 for the schedule of enrolment, interventions
and assessments.
Allocation and protecting against bias
Randomisation will occur immediately after baseline
data is submitted on the trial database and randomisa-
tion system. Participants will receive the first message
the day after they install the app. The allocation
sequence is generated by the remote, computer-based
randomisation software, ensuring that investigators are
unaware of allocation before participants are rando-
mised. Due to the nature of the intervention, partici-
pants will be aware of the allocation soon after they start
receiving the messages. Local research staff collecting
outcome data will not be aware of allocation unless this
is revealed to them by the participant. Researchers who
analyse the data will be masked to treatment allocation.
Intervention delivery
After randomisation, the trial database and randomisa-
tion system will send the local SMS platform the follow-
ing information: allocation, time slot (participants can
choose to receive messages from 10:00 to 13:59, 14:00 to
18:59, or both), mobile phone number and marital
status. The platform will send the intervention or con-
trol messages. Messages sent will be recorded by the
local platform and will be monitored.
Sample size
The trial is powered to detect an increase in acceptabil-
ity of effective contraception. Four hundred and fifty-
four participants will allow for 90% power to detect a
15% absolute increase in acceptability, assuming 50%
acceptability in the control group (i.e. 50% in the control
vs. 65% in the intervention, corresponding to an odds
ratio of 1.86). The sample size was calculated using the
Fig. 2 Schedule of enrolment, interventions and assessments. *Plus: if participants report using an effective method, where they obtained it; current
pregnancy intention; whether they knew someone else that took part in the study and, if so, if they read each other’s messages (contamination); if
they have experienced physical violence since being in the study and if anything good or bad happened as a result of receiving the messages
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statistical software Stata 15.0 (syntax: power twopropor-
tions .50 .65, test(chi2) power(0.9)) [68]. A 50% accept-
ability baseline is used in the absence of published data
on acceptability in this context. If the actual baseline
acceptability is higher or lower than 50%, the trial is still
sufficiently powered to detect an absolute difference of
15%. For example, if the proportion in the control arm is
75%, there will be 90% power to detect an absolute
difference of 12% (corresponding to 87% acceptability in
the intervention group and an odds ratio of 2.23). Allow-
ing for 20% loss to follow-up, 570 people will be
randomised.
Data management
We did not convene a Data Monitoring and Ethics
Committee as the intervention provides support and is
unlikely to produce adverse effects. However, we have
convened a Trial Steering Committee and they have
agreed to take on the monitoring of ethical aspects of
the trial. The trial sponsor may audit the trial according
to their own risk assessment and schedule.
Personal details entered onto the trial database and
randomisation system will be stored on LSHTM’s secure
server. Personally identifiable information exported from
the database will be stored separately from anonymised
research data on an LSHTM computer. Participant mo-
bile phone numbers, but no other personal details, will
be stored in the local platform that sends out the text
messages. Signed paper Consent Forms and question-
naires will be kept in a data enclave at PFPPA. All data
arising from the study will be kept confidential and is
only accessible to researchers directly involved in it. Per-
sonally identifiable data will not be kept longer than ne-
cessary and will be deleted within 3 months following
study completion. We will retain primary research data
for 10 years following study completion.
Analyses
General statistical considerations
The analysis of the data will follow the plan specified
below. There will be no interim analyses and, therefore,
no stopping rules. All analyses will be according to
randomised arm and only participants with complete
outcome data will be included in the primary analysis (a
complete case analysis). All statistical tests will be two-
sided. All effect estimates will be reported with a 95%
confidence interval and its associated p value. Statistical
significance will be considered at the 5% level. Analyses
will be conducted using the latest version of Stata.
Loss to follow-up
To investigate whether loss to follow-up differs by arm,
we will report this descriptively and use a chi-squared test.
We will use logistic regression to compare baseline
characteristics of participants who completed 4-month
follow-up against participants who did not. We will report
predictors of loss to follow-up and investigate whether the
effect of these differs by arm by testing for an interaction.
Assumptions about missing data
As we are not aware of similar trials, it is not possible to
investigate the pattern of missing data. The complete
case analysis assumes that missing data for participants
who did not complete follow-up are similar to data from
participants who did complete follow-up, conditionally
on baseline covariates included in the analysis model
(i.e. that data is missing at random (MAR)) [69]. If
participants who complete follow-up are more likely to
find an effective method acceptable compared to those
that are lost to follow-up, the observed proportion may
overestimate acceptability [69]. European Union guid-
ance on missing data in clinical trials highlights this
limitation of MAR among others [70]. The guidance
states, however, that ‘under reasonable assumptions’ the
estimate of treatment effect is unlikely to be biased ‘to
an important degree’. We will conduct the principal
analysis under a MAR assumption (conditionally on the
adjustment variables in the model), then perform sensi-
tivity analysis under different assumptions for the miss-
ing data, as explained below.
Missing covariates
The database requires all items on the baseline question-
naire to be submitted to randomisation. Therefore, there
will be no missing baseline covariates.
Principal analyses
Descriptive analysis We will report a flow diagram of
trial participation, as recommended in the CONSORT
guidelines [71]. We will report the baseline characteris-
tics by treatment arm. We will also explore the baseline
factors associated with retention (see above).
Analysis of the primary outcome The primary out-
come is binary and we will compare the crude propor-
tion reporting that at least one method is acceptable in
each group. We will estimate the difference between the
groups using logistic regression and will report the odds
ratio along with the 95% confidence interval and its p
value for evidence against the absence of intervention
effect from the model. The primary analysis regression
will be adjusted for baseline covariates likely to be asso-
ciated with the outcome in order to improve the effi-
ciency of the analysis and avoid chance imbalances [72].
These pre-specified covariates that we will adjust for are:
pregnancy intention (wants to avoid/other); age (18–19/
20–24 years); number of children (0/1+); highest
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education level completed (university/other) and accept-
ability of effective contraception at baseline (at least one
method acceptable/no methods acceptable). We will also
report the crude odds ratio between arms.
Analysis of the secondary outcomes The analysis of
the secondary outcomes will be the similar to the
analysis of the primary outcome. We will estimate the
difference between the groups using logistic regression,
report odds ratios with 95% confidence intervals and
their p values. All regressions will be adjusted for the
pre-specified covariates as above (although with the
acceptability of individual methods, the outcome at base-
line will replace acceptability of effective contraception).
Analysis of the process outcomes The process out-
comes perceived norms, personal agency and intention
are comprised of ordinal scales. Each scale will be
analysed individually using ordered logistic regression to
estimate proportional odds ratios. For knowledge, each
correct answer will receive 1 point. The points will be
summed and an overall score will be produced. We will
use linear regression to test for a difference in mean
scores between the arms.
To assess the ‘dose’ of the intervention that the inter-
vention participants received, we will analyse the num-
ber of messages that participants reported to have read
(all, most, some, none) and whether they stopped the
messages. This will be reported descriptively.
Additional analyses
Sensitivity analyses We will conduct sensitivity analyses
regarding the missing data assumptions. In the first sen-
sitivity analysis, we will consider that data are not MAR,
and that all participants lost to follow-up did not find at
least one method acceptable. In the second, we will ad-
just for the main baseline predictors of missingness.
Both sensitivity analyses will be adjusted for the pre-
specified covariates as above.
Subgroup analysis Recognising that the trial is not pow-
ered to detect effect differences in subgroups, we will con-
duct exploratory subgroup analyses for the primary
outcome to determine if the intervention effect varies by
baseline characteristics. The pre-specified subgroups are:
age (split at the median); marital status (married/not mar-
ried); number of children (0/1+); residence (city/other);
occupation (in education/other); highest education level
completed (university/other) and pregnancy intention
(wants to avoid/other). Within the pre-specified sub-
groups, we will assess heterogeneity of treatment effect
with a test for interaction [73–77]. Interaction test p
values will be presented but will be interpreted with
caution due to the exploratory nature, the multiple tests
performed and of the low power of the interaction test.
We will estimate odds ratios along with 95% CIs for each
subgroup without p values. As this is an exploratory ana-
lysis of potentially influential characteristics that are not
justified a priori, we will not hypothesise effect directions.
Contamination To assess the potential for contamin-
ation, we will report the proportion of control group
participants who read another participant’s messages
and the proportion of intervention participants whose
messages were read by another participant.
Analysis of pooled trial data We are conducting trials
of similar interventions in two other countries. If the re-
sults of the other trials are available, we will conduct the
principal analyses on the pooled dataset.
Participants’ rights and safety
Participants will have the right to withdraw at any time
during their involvement, without having to give a reason.
Participants can withdraw by contacting the project co-
ordinator. Acting on participants’ requests to withdraw
from the trial, participants’ status will be changed to ‘with-
drawn’, the text messages will stop and the person will be
excluded from the list of participants who are due follow-
up. Participants will be able to stop text messages, but
choose to continue with the trial follow-up. Participants’
participation and personal identifiable data will remain
confidential and research data will be anonymised.
In the formative work, we explored young people’s
views on confidentiality about receiving messages on
their mobile phone. While the large majority of partici-
pants did not report that they were concerned about
receiving messages about contraception on their mobile
phone, it is possible that some participants will want to
keep the messages confidential from certain people (e.g.
partner, parents) and that these people might view the
messages. The messages remind participants that they
can delete the messages and provide instructions on
how to keep the messages private. We will provide infor-
mation on support services that they can contact if they
feel unsafe because of the messages being read. We will
review physical violence during participants’ involvement
in the trial reported on the follow-up questionnaire.
Discussion
The results of this trial will provide evidence for the
effect of the intervention on young Palestinian women’s
attitudes towards effective contraception. The analysis of
the secondary and process outcomes may provide evi-
dence for the effect of the intervention on the use of ef-
fective contraception, attitudes towards the individual
effective methods, service use, unintended pregnancy,
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induced abortion and on the psychological processes
hypothesised to influence contraceptive use.
There are a number of limitations of this trial. The main
limitation is that the primary outcome is self-reported. As
sexual activity before marriage is highly stigmatised in
Palestine, this precluded the option of an objective
primary outcome in the study population. We expect that
a significant proportion of participants in the trial will not
be married and either will not be sexually active, or will be
unwilling to admit if they are. Powering a study for uptake
of contraception in a population, which will likely result in
a small number of outcome events, would make the
sample size prohibitively large. In not married/not sexually
active young women, the intervention aims to improve at-
titudes towards the most effective methods, so that they
will find a wider range of methods acceptable if they want
to choose a method in the future.
While local research staff are not made aware of
allocation, there is a chance that the participants could
reveal to local research staff collecting outcome data the
group that they were allocated to. Staff are trained in
asking questions in a standardised way. As the commu-
nities from which the trial participants derive are close,
we anticipate that there will be some degree of contam-
ination but we cannot predict the extent of it. We are
measuring the potential for contamination at 4-month
follow-up and will consider this when interpreting the
results. In absence of further data, we have powered the
trial to detect an absolute difference of 15% in the
proportion of participants finding at least one method of
effective contraceptive acceptable. The trial will have a
lower power if the intervention has a smaller effect.
Trial status
Recruitment commenced on 8 December 2016 and is will
be complete by 31 July 2017. The estimated completion
date for the final participant recruited (final data collec-
tion date for the primary outcome) is January 2018.
Additional files
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